Fremanezumab Phase III Migraine Trial

Fremanezumab is a drug being developed by Teva Pharmaceuticals for the prevention of migraine. Fremanezumab is a monocolonal antibody and a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP).  Results of the phase III clinical trial were published in Nov., 2017, in the New England Journal of Medicine. This study showed that fremanezumab was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. It is estimated that between 127 and 300 million people in the entire world experience chronic migraine, with 15 or more headaches per month for at least three months. Those who experience such intense and chronic migraines have a tough time finding effective relief. As such fremanezumab has been developed to hopefully help those who suffer and do not have any current medication that is effective. … Read more

Sphenopalatine Ganglion (SPG) Block for Headache Relief

Sphenopalatine Ganglion (SPG) block has been shown to help provide migraine headache relief for both children and adults. A small flexible catheter is inserted into each nostril and a local anesthetic is administered to the SPG, a nerve bundle thought to be associated with migraines, located at the back of the nose.  The anesthetic briefly disables the SPG and can disrupt and reset the headache circuit, which can break a cycle of severe migraines. A SPG block takes almost immediate effect with relief potentially lasting for many months. The SPG blocks have been performed in children. A child qualifies for the treatment if he/she has been diagnosed with a severe migraine and that migraine has not responded favorably to first-line medications and treatments. This form of treatment can be performed in an outpatient setting by an interventional radiologist. It can … Read more

Exploring the Prevalence of Generalized Anxiety Disorder in Adults with Migraine

Researchers at the University of Toronto have shown that generalized anxiety disorder is more common among adults who have migraines than those without migraine (6% vs. 2%). The link between migraine and generalized anxiety disorders was partially explained by the high prevalence of debilitating chronic pain (30%) and problems in managing household responsibilities (28%) among those with migraine. The researchers were not surprised chronic pain played a role in the association between migraines and generalized anxiety disorders. The unpredictable and uncontrollable nature of migraine pain can be anxiety producing as it can interfere with family and work responsibilities without warning. The study found men with migraine had almost double the odds of generalized anxiety disorder compared with women with migraine. The researchers found this result to be surprising because in the general population, women are more likely than men to develop … Read more

A Healthy Headache Diet

Researchers at the University of Cincinnati (UC) College of Medicine have explored two different approaches to preventing headaches with diet. The first approach is to eliminate foods and beverages known to trigger headaches. The second approach is to follow a diet whose very composition may prevent headaches. The conclusions were reached after performing an exhaustive literature review of more than 180 research studies on the subject of migraine and diet. The first thing to eliminate in your day to prevent headache is the morning cup of joe or coffee in the morning. This is because too much caffeine can lead to a caffeine withdrawal headache. The researchers say that no more than 400 milligrams daily of coffee should be used and one cup of 125 milligrams of coffee is the maximum amount a headache suffered should have. Large amounts of … Read more

Vitamin D deficiency and increased chronic headaches

Researchers from the University of Eastern Finland have shown that a vitamin D deficiency may increase the risk of chronic headache. The Kuopio Ischaemic Heart Disease Risk Factor Study, analysed the serum vitamin D levels and occurrence of headache in approximately 2,600 men between 42 and 60 years old in 1984-1989. In 68% of these men, the serum vitamin D level was below 50 nmol/l, which is generally considered to be a vitamin D deficiency. In the study chronic headache occurring at least once a week occurred in 250 men, and men reporting chronic headache had lower serum vitamin D levels than others. The study population was divided into four groups based on their serum vitamin D levels. The group with the lowest vitamin D levels had over a twofold increased risk of chronic headache in comparison to the group … Read more